In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Threshold Pharmaceuticals Inc.

Division of Molecular Templates Inc.
www.thresholdpharm.com

Latest From Threshold Pharmaceuticals Inc.

Deals Shaping The Medical Industry, July 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.

Deals BioPharmaceutical

Pipeline Watch: Phase III Progress With Anacetrapib, ALKS 3831 And LentiGlobin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Deals M & A

Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones

Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.

Commercial Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Molecular Templates Inc.
  • Senior Management
  • Barry Selick, PhD, CEO
    Eric Malek, SVP, Corp. Dev.
    Tillman Pearce, MD, CMO
    Joel A Fernandes, SVP, Fin.
  • Contact Info
  • Threshold Pharmaceuticals Inc.
    Phone: (650) 474-8200
    170 Harbor Way
    Ste. 300
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register